{"entity":{"id":"dar","kind":"term","name":"Drug-to-antibody ratio (DAR)","aka":["drug-to-antibody ratios"],"tldr":"The drug-to-antibody ratio (DAR) is how many payload molecules ride on each antibody, typically 2 to 8.","summary":"The drug-to-antibody ratio, or DAR, is the number of payload molecules attached to each antibody in an antibody-drug conjugate, typically between 2 and 8. A higher DAR delivers more drug per binding event, as with T-DXd at roughly 8 and sacituzumab at about 7.6, but it increases hydrophobicity, aggregation and clearance unless hydrophilic linkers compensate. Site-specific conjugation gives a homogeneous DAR, which improves pharmacokinetics. The term belongs to the Antibody-drug conjugate (ADC) and Site-specific conjugation & linker chemistry technologies, is picked up by the Hydrophilic next-generation linkers term, and appears in the DESTINY-Breast03 paper and the idea on ADC dose and schedule optimisation trials.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Antibody-drug_conjugate","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Antibody-drug_conjugate"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc","site-specific-conjugation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/dar/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"}],"idea":[{"id":"idea-tr1-adc-dose-and-schedule-optimisation","kind":"idea","name":"Dose and schedule optimisation trials specific to antibody-drug conjugates","route":"/ideas/idea-tr1-adc-dose-and-schedule-optimisation/"}],"paper":[{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/"}],"term":[{"id":"hydrophilic-next-gen","kind":"term","name":"Hydrophilic next-generation linkers (TMALIN, Dolaflexin, sulfonyl-pyrimidine, PEG-containing)","route":"/terms/hydrophilic-next-gen/"}]}}